Editorial: Psychological Factors as Determinants of Medical Conditions

Martino, Gabriella; Langher, Viviana; Cazzato, Valentina; Vicario, Carmelo M.

doi:10.3389/fpsyg.2019.02502

Cited by 35 publications

(31 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…AIs treatment has been associated with adverse events such as increased bone loss, musculoskeletal pain, impaired lipid profile and cardiovascular risk, but also with mood disturbances, anxiety and memory deficit [6][7][8]. Physical and psychological side effects seriously impair women's psychological balance and perceived QoL and may negatively influence the participation in medical care and adherence to every fundamental prescription [9][10][11][12][13][14][15][16][17]. In fact, several studies demonstrate the importance played by traumatic factors both on mental health and mood which could also lead to an increased suicidal risk and cognitive decline [18][19][20][21][22][23][24].…”

Section: Introductionmentioning

confidence: 99%

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

Introduction Aromatase inhibitors (AIs) dramatically increased breast cancer (BC) survival, leading to enhanced attention to their long-term consequences on psychological functioning. Conflicting data has been examined regarding the association between AIs administration and the clinical psychological features in BC survivors (BCSs). Purpose As psychological symptoms often occur in such chronic diseases, our study aimed at exploring anxious and depressive symptoms and the perceived quality of life (QoL) in BCSs assessed for osteoporosis. Methods The total sample consisted of a clinical sample of 51 outpatient postmenopausal women, diagnosed with BC, and a control group composed of 51 healthy postmenopausal women. All recruited participants were evaluated through the clinical gold standard interview and completed the following self-rating scales: the Hamilton Anxiety Rating Scale, Beck Depression Inventory II edition, and 36-Item Short Form Health Survey, which were administered at baseline and after 6 months in BCSs in AIs treatment, compared with controls. Moreover, all participants were assessed for vitamin D status, bone mineral density (BMD) and subclinical vertebral fractures. Data regarding age, age at menopause, body mass index (BMI), smoking habits and alcohol consumption was collected.

show abstract

Section: Introductionmentioning

confidence: 99%

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

et al. 2020

Self Cite

View full text Add to dashboard Cite

show abstract

“…At the same time, some authors find the strong association between psychological factors and medical condition, as fibromyalgia, psoriasis, diabetes, where psychological distress and poor quality of life correlate with higher severity of the pathology (43,44). However, no work has been done on the combination of alexithymia and somatic symptoms with NSSI.…”

Section: Introductionmentioning

confidence: 99%

Using the Body When There Are No Words for Feelings: Alexithymia and Somatization in Self-Harming Adolescents

et al. 2020

View full text Add to dashboard Cite

The present case-control study aimed to investigate the relationship between alexithymia and somatic complaints in the psychopathological setting of non-suicidal self-injury (NSSI). A clinical sample of 134 adolescents (115 females; 85.5%) from 12 to 18 years old engaging in NSSI was compared with a control group of 243 high-school students (157 females; 64.6%) from 13 to 18 years old. Data were collected using two questionnaires: The Youth Self-Report 11-18 and the 20 Toronto Alexithymia Scale. In both cases and controls, the presence of somatization and alexithymia was associated with more severe psychopathological problems. Analyses were conducted to explore the association between somatic disorders and alexithymia. In the clinical group, somatic complaints were reported by 95.9% of alexithymic individuals, whereas only 44.3% of alexithymic adolescents reported somatic complaints. A one-way relationship emerged between somatization and alexithymia: while alexithymia would seem to be a factor associated with self-injury, somatic disorders were strongly associated with alexithymia, but not necessarily with self-injury. Among the self-harming adolescents, those with both alexithymia and somatization had a more severe psychopathological picture than the individuals with alexithymia but no somatization. This would suggest that, in the setting of NSSI, greater difficulty with identifying feelings is associated with somatization, and alexithymia would be an attribute common to self-harming behavior and somatization, both of which are characterized by the body being used to express psychological and emotional problems. Future research could further investigate alexithymia in self-harming individuals, in relation to any presence or absence of somatic disorders, with longitudinal assessments on any differences in their manifestation of self-injury and its psychopathological correlates.

show abstract

“…Although the preliminary results obtained with the DAS-1 provide evidence of its reliability, validity and usefulness, further studies are needed and many issues remain to be addressed to improve our understanding, with particular regard to psychological factors as determinants in the adjustment to such diseases as diabetes (Martino et al, 2019). Use of the DAS-1 to assess psychological adjustment to diabetes may help predict risk in people with T1D by identifying individuals with low levels of adjustment to the disease.…”

Section: Discussionmentioning

confidence: 99%

“…Scientific interest in understanding how psychological factors may determine medical conditions is growing. Psychological aspects may seriously impact somatic symptoms and medical outcomes, especially in chronic diseases (Martino et al, 2019). After the initial impact of the diagnosis of a chronic disease such as type 1 diabetes (T1D), an adjustment period begins in which the individual must learn to live with the disease, which implies that these patients must take actions to become accustomed to their new circumstances (de Ridder et al, 2008).…”

Section: Introductionmentioning

confidence: 99%

Development and Preliminary Validation of a New Type 1 Diabetes Adjustment Scale (DAS-1)

et al. 2020

View full text Add to dashboard Cite

Background: This study focuses on the development and validation of a new Type 1 Diabetes Adjustment Scale (DAS-1). Method: A total of 204 participants aged 15-65 with type 1 diabetes completed the self-report measures of the DAS-1, which includes clinical and psychological variables. Results: Robust confirmatory factor analysis detected a unidimensional structure of the item scores. The omega coefficient was 0.91 and test-retest reliability was 0.87. Classifying subjects as in a Positive or Negative mood state, ROC analysis yielded an optimal cutoff of 50 for the DAS-1 scores, with a clinical accuracy of AUC = 0.85. The DAS-1 demonstrated evidence of good reliability and acceptable construct validity. Conclusion: The DAS-1 demonstrated good clinical utility, good sensitivity and adequate specificity. Clinical and theoretical implications of these results are discussed.

show abstract

Editorial: Psychological Factors as Determinants of Medical Conditions

Cited by 35 publications

References 28 publications

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Quality of life and psychological functioning in postmenopausal women undergoing aromatase inhibitor treatment for early breast cancer

Using the Body When There Are No Words for Feelings: Alexithymia and Somatization in Self-Harming Adolescents

Development and Preliminary Validation of a New Type 1 Diabetes Adjustment Scale (DAS-1)

Contact Info

Product

Resources

About